SLFN11 and small cell lung carcinoma: To confirm this, the randomized phase II SWOG S1929 trial was designed to evaluate whether the addition of talazoparib to atezolizumab maintenance in patients with SLFN11-positive SCLC demonstrates a benefit in terms of higher ORR, and longer PFS and OS [178].